SpyBiotech Ltd, a spin-out of the University of Oxford, has appointed Mark Leuchtenberger as chief executive and a member of the company’s board of directors. Mr Leuchtenberger was recently executive chairman of Aleta Biotherapies Inc and before that, CEO of Brooklyn ImmunoTherapeutics Inc, both in the US. With his joining, SpyBiotech has opened an office in Cambridge, US, to advance its vaccine platform which binds antigens to vaccine delivery platforms.
SpyBiotech announced the appointment on 12 July 2022
Copyright 2022 Evernow Publishing Ltd